Humira Market (2025 - 2030)

Humira Market Summary

The global Humira market size was estimated at USD 10.34 billion in 2024 and is projected to reach USD 4.11 billion by 2030, growing at a CAGR of -11.29% from 2025 to 2030. The market decline is primarily attributed to the increasing availability of biosimilars following patent expirations.

Despite a continued prevalence of autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease, the competitive landscape intensifies with the entry of cost-effective alternatives. Although pharmaceutical companies continue investing in R&D and pursuing geographic expansion and collaborations, pricing pressures and shifts in patient preference toward newer therapies are expected to further impact Humira’s market share.

The expansion of biosimilars is reshaping the Humira market by increasing accessibility and affordability. In 2024, the U.S. Food and Drug Administration (FDA) approved numerous biosimilars, such as Amjevita, Hyrimoz, and Yuflyma, which have introduced significant pricing competition, reducing treatment costs and expanding patient access. Healthcare providers and insurers are increasingly adopting biosimilars, driving broader use of adalimumab in autoimmune disease management. In response, AbbVie has introduced innovations, such as citrate-free formulations, to maintain product differentiation. The growing presence of biosimilars enhances overall adalimumab utilization, supporting market volume despite price erosion. However, the market's growth is declining, even as the increasing disease prevalence supports sustained demand for biologic therapies like Humira.

The rising global prevalence of autoimmune diseases remains a structural driver for the Humira market. A 2023 study published by The Lancet, involving 22 million individuals, estimated that autoimmune diseases affect approximately one in ten people worldwide. Genetic predisposition, environmental triggers, and improved healthcare access drive this growth. Higher prevalence rates are reported in Northern Europe and North America, where advanced diagnostics and disease awareness are well established. In emerging markets across Asia, Africa, and Australia, industrialization and lifestyle changes contribute to a sharp increase in incidence rates. The expanding global autoimmune patient pool supports sustained demand for biologic therapies such as Humira.

The rising burden of Crohn’s disease further contributes to Humira demand. Data from Minnesota indicates that 19% of Crohn’s patients present with complications within 90 days of diagnosis, and 50% develop intestinal complications over 20 years. Crohn’s disease typically affects the ileum, the ileocolonic region, or the colon, with limited migration over time. Humira remains a long-term treatment option across all disease locations. Incidence is highest among Northern Europeans and individuals of Jewish descent, but emerging markets in Asia, Africa, and Australasia are witnessing increasing rates due to industrialization. The chronic and progressive nature of Crohn’s disease supports ongoing therapeutic demand.

While Humira faces a declining revenue trajectory due to biosimilar competition and loss of exclusivity, these underlying drivers continue to stabilize market volumes. The global expansion of autoimmune diseases, broader biosimilar adoption, and the increasing burden of Crohn’s disease maintain demand for adalimumab therapies. Additionally, biosimilars are unlocking previously untapped markets by making biologic treatment accessible at lower costs. As a result, although the market value is contracting, the overall volume of adalimumab utilization remains supported by fundamental growth factors.

Pipeline Analysis

The following analysis outlines key developments in the pipeline for autoimmune and inflammatory conditions, focusing on drugs targeting diseases such as rheumatoid arthritis, ulcerative colitis, and plaque psoriasis. Notable highlights include several promising treatments advancing through Phase 3 trials, including adalimumab for plaque psoriasis and ulcerative colitis, with launches expected between 2027 and 2030. Upadacitinib, aimed at rheumatoid arthritis, and Ixekizumab, for juvenile psoriatic arthritis, also show strong potential, with anticipated launches during the forecast period. The progress across various phases underscores the ongoing innovation in the autoimmune therapeutics market, with several therapies poised to address unmet clinical needs.

The China Humira market is rapidly becoming a biosimilar powerhouse, with government policies encouraging fast-track approval and pricing regulation of biologics. Humira biosimilars are included in public insurance plans, while e-commerce health platforms and hospital-private partnerships enhance distribution.

Latin America Humira Market Trends

Latin America shows moderate but steady growth, with Brazil and Argentina leading. Biosimilar penetration is increasing due to economic constraints and updated public health procurement policies. Collaborations with global pharma companies are helping local firms scale production and improve quality standards.

The Brazil Humira market is expanding amid high autoimmune disorder incidence and support for biosimilar adoption. The government has prioritized chronic disease treatments under the SUS (Unified Health System), boosting availability in public hospitals. Local production and international licensing deals are further driving market accessibility.

Middle East & Africa Humira Market Trends

The Middle East and Africa are emerging markets for Humira, led by Saudi Arabia and the UAE. Government initiatives like Vision 2030 (Saudi Arabia) and healthcare digitalization (UAE) support biologics infrastructure. Local distributors are increasingly partnering with global biosimilar producers to ensure affordability and access.

The Saudi Arabia Humira market is expanding due to significant biopharma investments and rising rates of autoimmune and metabolic diseases. Health insurance reforms and government funding are facilitating biosimilar uptake. E-pharmacy platforms and telemedicine services are broadening access across urban and rural areas.

Key Humira Company Insights

The Humira market has entered a phase of rapid evolution following the drug’s loss of exclusivity in key global markets. In 2024, the competitive intensity has grown considerably, with a surge of biosimilars securing regulatory approvals and launching across various regions. This progression is significantly altering the competitive landscape by lowering treatment costs for healthcare systems and improving access for patients with autoimmune and inflammatory disorders.

New entrants in the biosimilar segment are employing advanced strategies, including high-concentration, citrate-free formulations and interchangeable approvals, to distinguish their offerings. Many companies are forming strategic alliances with multinational pharmaceutical firms to leverage established manufacturing infrastructure, global supply chains, and in-market expertise. These developments are contributing to a more diversified and accessible biologics market worldwide.

Recent Developments

• In April 2025, the U.S. Food and Drug Administration granted interchangeable status to YUFLYMA, a high-concentration, citrate-free biosimilar of Humira, developed by Celltrion, Inc. The designation applies across multiple inflammatory indications and allows pharmacists to substitute YUFLYMA for Humira without requiring a new prescription.

• In October 2024, Prime Therapeutics introduced new biosimilar strategies to expand access to cost-effective Humira alternatives. Starting in 2025, Prime will recommend biosimilars from four manufacturers: Organon (Hadlima), Teva (Simlandi), Sandoz (adalimumab-adaz), and Celltrion (adalimumab-aaty), offering flexible plan options including biosimilars-first or biosimilars-only models. These offerings include low-list-price biosimilars, with net monthly costs as low as USD 500-USD 600. They are supported through Prime’s conflict-free specialty pharmacy network, helping ensure broader access and affordability for millions of Americans.

• In December 2023, Biocon Biologics Ltd. (BBL), a global biosimilars company and subsidiary of Biocon, entered into a strategic distribution agreement with Sandoz. Under this agreement, Sandoz was granted exclusive rights to promote, sell, and distribute Adalimumab BS for subcutaneous injection (a biosimilar to Humira) in Japan.

Humira Market